Neurogene Inc.
$27.74
▼
-4.48%
2026-04-21 08:24:00
www.neurogene.com
NGM: NGNE
Explore Neurogene Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$432.03 M
Current Price
$27.74
52W High / Low
$37.27 / $10.46
Stock P/E
—
Book Value
$17.1
Dividend Yield
—
ROCE
-37.96%
ROE
-31.41%
Face Value
—
EPS
$-4.24
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
131
Beta
1.89
Debt / Equity
3.73
Current Ratio
16.56
Quick Ratio
16.56
Forward P/E
-3.68
Price / Sales
—
Enterprise Value
$58.28 M
EV / EBITDA
-0.58
EV / Revenue
—
Rating
Strong Buy
Target Price
$77.67
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Compass Therapeutics, Inc. | $5.42 | — | $1.08 B | — | -35.42% | -41.29% | $6.88 / $1.6 | $1.1 |
| 2. | Exelixis, Inc. | $46.57 | 16.78 | $11.84 B | — | 36.6% | 35.53% | $49.62 / $33.76 | $8.23 |
| 3. | Tenaya Therapeutics, Inc. | $0.74 | — | $169.71 M | — | -70.98% | -83.84% | $2.35 / $0.36 | $0.57 |
| 4. | REGENXBIO Inc. | $9.47 | — | $488.82 M | — | -48.13% | -1.07% | $16.19 / $5.85 | $2.02 |
| 5. | vTv Therapeutics Inc. | $37.75 | — | $157.78 M | — | -39.41% | -78.94% | $44 / $14 | $5.19 |
| 6. | Nutriband Inc. | $4.2 | — | $51.13 M | — | -103.12% | -1.36% | $11.68 / $3.42 | $0.62 |
| 7. | Acumen Pharmaceuticals, Inc. | $2.84 | — | $203.64 M | — | -133.4% | -96.2% | $3.6 / $0.85 | $1.16 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -27.53 M | -23.8 M | -26.08 M | -25.92 M | -21.51 M | — |
| Net Profit | -24.73 M | -20.95 M | -22.02 M | -22.65 M | -19.51 M | — |
| EPS in Rs | -1.59 | -1.35 | -1.41 | -1.45 | -1.25 | -1.19 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0.93 M | 0 M | 0 M |
| Operating Profit | -103.33 M | -82.61 M | -55.58 M | -56.52 M |
| Net Profit | -90.35 M | -75.14 M | -36.32 M | -55.19 M |
| EPS in Rs | -5.8 | -4.82 | -2.33 | -3.54 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 288.6 M | 335.73 M | 222.57 M | 109.27 M |
| Total Liabilities | 23.72 M | 25.36 M | 36.55 M | 255 M |
| Equity | 264.89 M | 310.38 M | 186.02 M | -145.74 M |
| Current Assets | 271.77 M | 315.92 M | 200.35 M | 84.72 M |
| Current Liabilities | 16.41 M | 15.16 M | 22.97 M | 6.65 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -77.17 M | -70.6 M | -51.42 M | -52.82 M |
| Investing CF | 14 M | -125.26 M | 25.64 M | -2.23 M |
| Financing CF | 30.43 M | 184.07 M | 92.48 M | 66.53 M |
| Free CF | -78.36 M | -71.41 M | -51.74 M | -55.05 M |
| Capex | -1.18 M | -0.81 M | -0.32 M | -2.23 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -106.91% | 34.2% | — | — |
| Profit Margin % | -8123.68% | — | — | — |
| Operating Margin % | -8930.27% | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -7771.35% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-12-19 | 1:0.25 |
| 2023-09-25 | 1:0.2 |